Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• patients between the ages of 15 and 80 years

• with clinical symptoms of acid regurgitation, heart burn, or feeling of acidity in the stomach,

• who have Los Angeles Grade A and B erosive esophagitis proven by endoscopy are recruited.

Exclusion Criteria:

1. coexistence of peptic ulcer or gastrointestinal malignancies,

2. pregnancy,

3. coexistence of serious concomitant illness (for example, decompensated liver cirrhosis and uremia),

4. previous gastric surgery,

5. allergy to esomeprazole,

6. symptom score of a validated questionnaire (Chinese GERDQ) less than 12, and

7. equivocal endoscopic diagnosis of Los Angeles Grade A and B erosive esophagitis.